These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 17156479)

  • 41. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services.
    McEwen A; West R
    BMC Public Health; 2009 Jan; 9():28. PubMed ID: 19159473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressants for smoking cessation.
    Hughes JR; Stead LF; Hartmann-Boyce J; Cahill K; Lancaster T
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD000031. PubMed ID: 24402784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. General practitioner prescribing of single and combination nicotine replacement therapy in the UK: a retrospective database study.
    Johnson M; Anderson P; Lockhart I
    BMC Fam Pract; 2014 Mar; 15():47. PubMed ID: 24645823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.
    Aubin HJ; Bobak A; Britton JR; Oncken C; Billing CB; Gong J; Williams KE; Reeves KR
    Thorax; 2008 Aug; 63(8):717-24. PubMed ID: 18263663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.
    Hays JT; Ebbert JO
    Drugs; 2010 Dec; 70(18):2357-72. PubMed ID: 21142259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interventions to increase adherence to medications for tobacco dependence.
    Hollands GJ; McDermott MS; Lindson-Hawley N; Vogt F; Farley A; Aveyard P
    Cochrane Database Syst Rev; 2015 Feb; (2):CD009164. PubMed ID: 25914910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological interventions for promoting smoking cessation during pregnancy.
    Coleman T; Chamberlain C; Davey MA; Cooper SE; Leonardi-Bee J
    Cochrane Database Syst Rev; 2012 Sep; (9):CD010078. PubMed ID: 22972148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterising the use of varenicline: an analysis of the Australian dispensing claims data.
    Gobarani RK; Ilomäki J; Wood S; Abramson MJ; Bonevski B; George J
    Addiction; 2022 Oct; 117(10):2683-2694. PubMed ID: 35603915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interventions to increase adherence to medications for tobacco dependence.
    Hollands GJ; Naughton F; Farley A; Lindson N; Aveyard P
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009164. PubMed ID: 31425618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
    King DP; Paciga S; Pickering E; Benowitz NL; Bierut LJ; Conti DV; Kaprio J; Lerman C; Park PW
    Neuropsychopharmacology; 2012 Feb; 37(3):641-50. PubMed ID: 22048466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
    Taylor M; Leonardi-Bee J; Agboola S; McNeill A; Coleman T
    Addiction; 2011 Oct; 106(10):1819-26. PubMed ID: 21561499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.
    Coleman T; Agboola S; Leonardi-Bee J; Taylor M; McEwen A; McNeill A
    Health Technol Assess; 2010 Oct; 14(49):1-152, iii-iv. PubMed ID: 21040645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytisine for smoking cessation: A systematic review and meta-analysis.
    Ofori S; Lu C; Olasupo OO; Dennis BB; Fairbairn N; Devereaux PJ; Mbuagbaw L
    Drug Alcohol Depend; 2023 Oct; 251():110936. PubMed ID: 37678096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis.
    Mills EJ; Wu P; Spurden D; Ebbert JO; Wilson K
    Harm Reduct J; 2009 Sep; 6():25. PubMed ID: 19761618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nicotine replacement therapy for smoking cessation.
    Silagy C; Mant D; Fowler G; Lancaster T
    Cochrane Database Syst Rev; 2000; (3):CD000146. PubMed ID: 10908462
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.